Fibrobiologics Stock Price, News & Analysis

FibroBiologics (NASDAQ: FBLG) has appointed Jason D. Davis, CPA, as Chief Financial Officer, effective immediately. Davis brings over 20 years of public company and capital markets experience, particularly valuable as the company prepares for its Phase 1/2 clinical trial for diabetic foot ulcers in H2 2025. Davis previously served as CFO at Virax Biolabs, where he led their successful IPO in 2022, and at HyperDynamics Corp, where he increased market cap from $20M to $700M+ and raised over $200M. FibroBiologics, a clinical-stage biotech company, holds 275+ patents focusing on fibroblast-based therapeutics for chronic diseases. The appointment strengthens the company's financial leadership as it advances its clinical programs and expands its therapeutic platform.

FibroBiologics (Nasdaq: FBLG) presented research findings at the Society for Investigative Dermatology Annual Meeting in San Diego. Dr. Chuo Fang delivered a poster presentation titled "Immunomodulatory Potential of Human Dermal Fibroblast Spheroids in Psoriasis Therapy" on May 9, 2025. The research showcased the potential of human dermal fibroblast (HDF) spheroids to reduce psoriasis severity in preclinical models. Chief Scientific Officer Dr. Hamid Khoja highlighted that their fibroblast-based candidate could offer a durable therapeutic option with unique immunomodulatory mechanisms, potentially providing sustained remission, reduced relapse, and fewer adverse side effects. FibroBiologics, a clinical-stage biotech company, holds 240+ patents/pending patents across various clinical pathways including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer.

FibroBiologics (NASDAQ: FBLG) reported its Q1 2025 financial results and corporate updates. The company plans to initiate a Phase 1/2 clinical trial for its fibroblast-based spheroids product CYWC628 for diabetic foot ulcers in Q3 2025. Key achievements include completing a proprietary master cell bank, opening a new Houston laboratory, and demonstrating successful remyelination in neurodegenerative disease research. Financial results showed R&D expenses of $1.8 million (up from $1.0M in Q1 2024), G&A expenses of $2.8 million (up from $2.5M), and a reduced net loss of $5.0 million (down from $8.5M). The company ended Q1 2025 with $8.7 million in cash and cash equivalents.

FibroBiologics (Nasdaq: FBLG), a clinical-stage biotech company with 240+ patents, announced its participation at the ThymUS 2025 Meeting in Hawaii. Research scientist Simon Gebremeskel will present findings on artificial thymus organoid development for generating functional T cells.

The company's Chief Scientific Officer, Dr. Hamid Khoja, highlighted the potential of artificial thymus organoids to restore thymus functionality, which serves as the T-cell teaching center of the immune system. The research demonstrates promising applications of organoids in treating chronic diseases, leveraging fibroblasts' unique immunomodulatory properties.

Key Company Highlights:

• Houston-based clinical-stage biotechnology firm
• Focuses on fibroblast cells and fibroblast-derived materials
• Developing treatments for multiple conditions including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, and cancer
• Holds extensive patent portfolio across various clinical pathways

FibroBiologics (Nasdaq: FBLG), a clinical-stage biotechnology company, announced its participation at The Cell & Gene Meeting On The Mediterranean in Rome from April 15-17, 2025. The company's Chief Scientific Officer, Dr. Hamid Khoja, will present on their innovative fibroblast cell-based therapeutic approach for chronic diseases.

The presentation, titled 'Restoring Immune system homeostasis using a fibroblast cell-based therapeutic targeting three chronic inflammation-mediated diseases,' will take place on Wednesday, April 16 at 9:00 AM CEST at the Salone dei Cavalieri.

FibroBiologics specializes in developing treatments using fibroblast cells and fibroblast-derived materials, with a significant intellectual property portfolio of 240+ US and international patents. Their research spans multiple therapeutic areas including:

• Wound healing
• Multiple sclerosis
• Disc degeneration
• Psoriasis
• Orthopedics
• Human longevity
• Cancer

FibroBiologics (Nasdaq: FBLG) has announced the opening of a new laboratory facility in Houston, Texas, marking a significant expansion of its research capabilities in fibroblast-based therapeutics. The new facility spans over 10,000 square feet of lab and office space, designed to accelerate the development of treatments for chronic diseases.

The expansion will enable the company to:

• Increase the pace of discovery for potential therapeutics
• Enhance development of treatment candidates
• Potentially bring GMP manufacturing in-house for drug product candidates
• Hire additional researchers

The company, which holds 240+ patents issued and pending, aims to streamline its supply chain and reduce reliance on external partners through this expansion. The facility will allow for broader pipeline exploration and more effective collaboration in developing fibroblast-based technology.

FibroBiologics (Nasdaq: FBLG) has announced a breakthrough in neurodegenerative disease research through their Cuprizone animal model study. The research demonstrated that intravenous fibroblasts can significantly increase myelin expression within seven weeks using both single and multiple dose treatments.

This finding confirms their previous results from the Experimental Autoimmune Encephalomyelitis (EAE) animal model. The research focuses on myelin sheath regeneration, which is important for proper nerve function and often damaged in conditions like multiple sclerosis. The myelin sheath is essential for rapid neural communication, affecting functions such as thinking, memory, movement, and coordination.

The company, which holds 240+ patents issued and pending for fibroblast-based therapeutics, aims to develop treatments that address the root causes of chronic diseases rather than just symptoms.

FibroBiologics (NASDAQ: FBLG) has reported its full year 2024 financial results and corporate updates. The company completed its proprietary master cell bank for CYWC628, their fibroblast-based spheroids product candidate for diabetic foot ulcers (DFUs), meeting Good Manufacturing Practices requirements.

Key financial highlights include:

• Cash position of $14.0 million as of December 31, 2024
• R&D expenses increased to $4.5 million from $2.4 million in 2023
• G&A expenses rose to $9.2 million from $6.5 million in 2023
• Net loss decreased to $11.2 million compared to $16.5 million in 2023

The company secured a $25.0 million Standby Equity Purchase Agreement with Yorkville, with $10.0 million already advanced. FibroBiologics plans to initiate a Phase 1/2 clinical trial for CYWC628 in Australia during Q2 2025, with completion expected by year-end.

FibroBiologics (Nasdaq: FBLG), a clinical-stage biotechnology company, has announced its 2025 Annual Meeting of Stockholders, scheduled for June 12, 2025, at 11 a.m. CDT. The meeting will be held exclusively in a virtual format.

The company, which focuses on developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, has set April 14, 2025 as the record date for stockholder voting eligibility. FibroBiologics currently maintains a portfolio of 160+ US and international patents/patents pending across various clinical pathways, including:

• Disc degeneration
• Orthopedics
• Multiple sclerosis
• Psoriasis
• Wound healing
• Reversing organ involution
• Cancer